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Summary 
Diabetes in nonobese diabetic  (NOD)  mice is a T  cell-dependent autoimmune disease.  The 
destructive activities of autoreactive T  cells have been shown to be tightly regulated by effector 
molecules. In particular, T  helper (Th) 1 cytokines have been linked to diabetes pathogenesis, 
whereas  Th2 cytokines and the cells that release them have been postulated to be protective 
from disease. To test this hypothesis, we generated transgenic NOD mice that express interleu- 
kin  (IL)  4 in their pancreatic [3 cells under the control of the human insulin promoter. We 
found that transgenic NOD-IL-4 mice, both females and males, were completely protected 
from insulitis  and diabetes. Induction of functional tolerance to islet antigens in these mice was 
indicated by their inability to reject syngeneic pancreatic islets and the failure of diabetogenic 
spleen cells to induce diabetes in transgenic NOD-IL-4 recipients. Interestingly, however, islet 
expression of IL-4 was incapable of preventing islet rejection in overfly diabetic NOD recipi- 
ent mice. These  results  demonstrate that the Th2 cytokine IL-4 can prevent the development 
of autoimmunity and destructive autoreactivity in the NOD mouse. Its ability to regulate the 
disease  process  in the periphery also indicates that autoimmune diabetes in NOD  mice is not a 
systemic disease, and it can be modulated from the islet compartment. 
T 
he  nonobese  diabetic  (NOD) l  mouse  develops  au- 
toimmune  diabetes with immunopathological features 
resembling those of the human disease (1). In these mice, 
a pancreatic inflammation consisting of mononudear leu- 
kocytes first surrounds  and then infiltrates the  islets  and 
destroys the  insulin-producing  13  cells  (2).  T  cells  play a 
pivotal role in the development of this disease,  as demon- 
strated by antibody treatment (3-6) and splenocyte transfer 
experiments (7, 8). 
T  cells are important positive and negative regulators of 
(auto)immune responses. In humans and mice, at least two 
functionally distinct subsets  of T  cells exist, distinguishable 
by  the  cytokines  they  release  upon  activation  (9).  The 
CD4 +  compartment includes  Thl  and  Th2  subsets.  Thl 
cells release predominantly IFN-~/ and are  associated  with 
pathogenic autoimmunity, whereas  Th2 cells release IL-4 
and  IL-10 and  are  associated  with  allergic responses and, 
presumably,  inhibition  of spontaneous  autoimmune  dis- 
ease.  Apparently,  the  CD8 +  compamnent  also  contains 
two cell categories, TC1  and TC2, with cytokine profiles 
similar  to  those  of  the  CD4  compartment  (10-12).  The 
generation of both Th2 cells (13) and TC2 cells (11,  12) in 
t  Abbreviations used in this  paper: GAD, glutamic acid decarboxylase;  NOD, 
nonobese diabetic. 
vitro is critically dependent on the presence of IL-4 during 
T  cell priming. 
The immune system can be viewed as a dynamic balance 
between different types ofT cells; any disturbance that en- 
ables  one  T  cell  subcategory  to  become  dominant  may 
prove deleterious.  Indeed,  substantial  evidence has  linked 
the pathogenesis of diabetes in NOD mice to the preferen- 
tial  activation of the Thl  subset  (for review see reference 
14). Direct evidence for the pathogenic effects of Thl versus 
Th2 cells was  recently provided by the injection of Thl- 
and Th2-1ike effector cells into neonatal NOD mice: Thl 
cells rapidly promoted diabetes,  whereas  Th2 cells did not 
initiate the disease  (15,  16). Interestingly, in co-transfer ex- 
periments using these in vitro-differentiated Thl and Th2 
cells, the Th2 cells did not confer protection from diabetes 
(16). Yet, such transfer experiments with in vitro- "predif- 
ferentiated" T  cells of an individual clonotype do not re- 
flect the  situation in vivo in which antigen exposure and 
cytokine stimulation occur simultaneously within the lym- 
phoid organs or in tissues, and multiple clonotypes of vary- 
ing  affinity coexist.  Since  naive  islet-specific  T  cells  are 
likely to encounter islet  antigens in islets or adjacent lym- 
phoid aggregates,  we  hypothesized that in situ  expression 
of IL-4 within the  islets  could affect T  cells  that migrate 
within the pancreas, encouraging them to differentiate to- 
ward a nondestructive phenotype. 
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Generation of Transgenic Mice.  A  plasmid  containing  the  hu- 
man insulin promoter and the terminator sequence from the hep- 
atitis B  virus gene  (17)  was  cut  at  its unique  BamHI  site  and 
blunt-ended by the Klenow fragment ofDNA polymerase I. The 
451-bp HindlII/EcoRl fragment encoding murine IL-4 was ex- 
cised from a cDNA clone  (British Biotechnolog% Oxon,  UK), 
blunt-ended, and inserted into the insulin promoter-containing 
plasmid. The hybrid DNA molecule (ins-IL-4) was cleaved with 
EcoRl and Sphl, and the 3,097-bp fragment was isolated, puri- 
fied,  and  microinjected into  fertilized zygotes from  NOD/Shi 
mice from the Scripps rodent colony. The presence of the trans- 
gene was confirmed by PCR typing of tail DNA. All mice were 
housed together under specific pathogen-free housing conditions 
at the Scripps rodent colony. 
Islet and Thymocyte Culture and IL-4 Assay.  Islets  were  isolated 
from pancreata of 7-12-wk-old NOD-IL-4 mice and their non- 
transgenic littermates as described (18).  Briefly, pancreata were 
digested with collagenase P (Boehringer Mannheim Corp., India- 
napolis, IN)  and handpicked under an inverted microscope. 65 
individual islets were  cultured for 48  h  in  500  I.fl RPMI  1640 
medium supplemented with 20 mM Hepes, 2 mM r-glutamine, 
100  U/ml  penicillin,  100  b~g/ml  streptomycin, and  10%  FCS. 
Thymocytes from  three  NOD-IL-4  mice  and  three  nontrans- 
genic littermates were cultured (5 X  106/ml) in RPMI 1640 sup- 
plemented with 1 mM NaPyruvate, 2 mM L-glutamine, 0.05 mM 
2-ME,  100  U/ml penicillin, 100  ~g/ml streptomycin, and  10% 
FCS for 24 h  (19).  Supernatants from islet cells and thymocytes 
were removed, and IL-4 levels were determined with an ELISA 
assay using mAb BVD4-1D 11 and biotinylated Ab 11B 11 as cap- 
ture  and  detection Abs,  respectively (PharMingen,  San  Diego, 
CA). The concentration of IL-4 in samples was interpolated from 
a standard curve using recombinant routine IL-4 (PharMingen). 
This standard curve was linear in the range of 19-1,250 pg/ml. 
Measuring of Blood Glucose Levels.  Twice a month, blood was 
withdrawn from the retroorbital sinus  of anesthetized mice, and 
blood glucose levels were  determined using blood glucose test 
strips (Glucofilm; Miles Diagnostics Division, Inc., Elkhart, IN). 
Histological Evaluation of Pancreata.  Multiple hematoxylin and 
eosin-stained pancreatic sections from three to five mice in each 
age  group  were  scored  for  periinsulitis and  insulitis. Approxi- 
mately 20 islets were scored for each pancreas. 
Grafting of Islets.  For grafting into NOD-IL-4 females, islets 
were isolated from 4-5-wk-old NOD females as described above. 
120-150  islets were transplanted under the right kidney capsule 
of 10-11-too-old NOD-IL-4 females.  For grafting into diabetic 
NOD females,  islets were isolated from 5-6-wk-old NOD-IL-4 
females and their nontransgenic female littermates. 100-200 indi- 
vidual islets were grafted under the right kidney capsule of dia- 
betic NOD females.  All grafted kidneys were removed 4 wk after 
surgery, and the grafts were examined histologically. 
Splenocyte Transfer.  Donor  cell  suspensions  were  prepared 
from spleens of diabetic NOD females. Red cells were lysed with 
0.84%  ammonium  chloride. Remaining cells  were washed and 
resuspended at 108 cells/ml in sterile PBS. 8-9-wk-old recipient 
NOD  females  were  irradiated  (700  rad)  and  injected  intrave- 
nously with  200  I~1 of the  donor splenocyte suspension. Blood 
glucose  values were  determined weekly starting at  2  wk  after 
transfer. 
Immunohistochemical Staining.  Paraffin-embedded pancreata and 
graft tissue were stained with an immunoperoxidase method us- 
ing polyclonal Abs to porcine insulin (Dako Corp., Carpinteria, 
CA), synthetic glucagon (Chemicon International, Inc., Temec- 
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ula, CA, USA), and human somatostatin (Dako Corp.), followed 
by  a  biotinylated secondary Ab  and  an  avidin-biotin complex 
(Vector  Laboratories,  Inc.,  Burlingame,  CA).  Frozen  sections 
were stained with primary Abs to murine L3T4, Ly2, B 220  (all 
PharMingen),  and  F4/80  (Serotec Ltd.,  Oxford,  UK)  and  the 
same immunoperoxidase technique. 
Cytokine Release to Glutamic Acid Decarboxylase (GAD) Stimula- 
tion.  Spleen  cells  were  prepared  from  individual 7-8-wk-old 
NOD-IL-4  females  and  their  nontransgenic  female  littermates 
and incubated at 12  X  106/ml in 0.5 ml culture medium (RPMI 
1640,  1% Nutridoma, 5 X  10 -~ M  2-ME) in the presence or ab- 
sence  of 20  Ixg/ml human  GAD65  purified from recombinant 
bacteria (a  kind gift of Dr.  D.  Kaufman,  UCLA,  Los  Angeles, 
CA). After 72 h, supernatants were collected and analyzed for the 
presence of IFN-~/ and IL-4 using an ELISA assay. IFN-',/levels 
were  determined  using  mAb  R4-6A2  and  biotinylated  Ab 
XMG1.2  as capture and detection Abs, respectively (PharMin- 
gen).  The  concentration of IFN-',/ in  samples was  interpolated 
from a standard curve using recombinant murine  IFN-~/ (Phar- 
Mingen). This standard curve was linear in the range of 39-2,500 
pg/ml. IL-4 levels were determined as described as above. 
Results  and Discussion 
To  generate  transgenic  NOD  mice,  murine  IL-4  was 
targeted  to  the  pancreatic  islets  using  the  human  insulin 
promoter  (17,  20,  21).  The  Ins-IL-4 transgene  construct 
was  injected  into  fertilized  NOD  zygotes,  and  progeny 
positive for the Ins-IL-4 transgene were subsequently bred 
with  NOD  mice.  Using this  approach,  four  independent 
lines were obtained; one of these lines (designated NOD- 
IL-4 mice) was propagated for the current study. Appropri- 
ate  expression  of the  transgene  in  NOD-IL-4  mice  was 
verified at the mRNA  and protein level. In situ hybridiza- 
tion with probes that detect the IL-4 coding sequence con- 
firmed the exclusive localization of IL-4 to pancreatic islets 
in NOD-IL-4  mice  (data not shown).  To  ensure that this 
IL-4 mRNA  led to  the production  and secretion of IL-4 
protein,  islets were  isolated from  the pancreas  of NOD- 
IL-4 mice  and  their nontransgenic  littermates, cultured in 
vitro, and the amount  of IL-4 released by individual islets 
was determined with an ELISA assay. We found that 65 is- 
lets isolated from NOD-IL-4  mice secreted from 50 to 95 
pg IL-4/48  h.  These  amounts  are in the range  of that  re- 
leased  by  comparable  numbers  of stimulated  T  cells  (22, 
23)  and  allow the  differentiation of Th2  effectors in vitro 
(16).  IL-4 was not detectable in supernatants from islets of 
nontransgenic littermates. Constructs using the insulin pro- 
moter may direct expression of the  transgene  not  only to 
pancreatic J3 cells but also to the thymus  (24, 25).  Further- 
more, it has been shown  that IL-4, when selectively over- 
expressed in the thymus oftransgenic mice, significantly al- 
ters thymocyte development and thymus architecture (19). 
To  address possible transgene  expression in the thymus  of 
NOD-IL-4  mice,  IL-4  levels  in  supernatants  from  thy- 
mocytes after short-term in vitro culture were  determined 
using  an  ELISA  assay.  Thymocyte  cultures  from  neither 
NOD-IL-4  mice nor from their nontransgenic  littermates 
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Figure 1.  Cumulative diabetes incidence of  NOD-IL-4 mice and their 
nontransgenic littermates. Blood  glucose levels were  determined  bi- 
monthly using Glucofilm  blood glucose test strips. Mice were considered 
diabetic after two consecutive measurements >250 mg/dl.  Number of 
diabetic mice/total number of mice is given in parentheses. 
had detectable levels of IL-4, demonstrating that there was 
no  significant  amount  of IL-4 released  from  their  thymi. 
Hematoxylin  and  eosin-stained  paraffin  sections  from 
thymi of NOD-IL-4  mice were  further  examined for the 
histological changes described previously (19). Thymi from 
NOD-IL-4 mice showed normal architecture and were in- 
distinguishable  from  thymi  of their  nontransgenic  litter- 
mates,  rendering thymic expression of the transgene highly 
unlikely. 
To determine  whether in situ  expression  of IL-4 affects 
the  development  of diabetes,  NOD-IL-4  mice  and  their 
nontransgenic  littermates  were  measured  for  nonfasting 
blood  glucose  levels  (Fig.  1).  Nontransgenic  NOD  mice 
spontaneously developed diabetes  starting at  18 wk of age, 
the  cumulative  incidence  of diabetes  reaching  75%  in  fe- 
males and 25% in males by 28 wk of age, respectively. This 
disease course duplicated the one of our conventional SPF- 
NOD  colony.  In sharp  contrast,  none  of the  NOD-IL-4 
mice, female or male, became diabetic during the  1-yr ob- 
servation  period.  During  the  whole  observation  period, 
blood glucose values  of these  mice stayed below 200 mg/ 
dl.  Histological  analysis  of pancreata  from  nontransgenic 
NOD  mice at the onset of diabetes revealed severe insulitis 
in  a  majority  of islets  (Fig.  2  A).  However,  pancreata  of 
NOD-IL-4  mice at 9-11  mo of age contained intact islets 
occasionally surrounded  by inflammatory  cells  (periinsuli- 
tis),  but  destructive  insulitis  was  never  detected  (Fig.  2  /3). 
Normal islet architecture and intact islet mass in NOD-IL-4 
mice were  furthermore  confirmed using antibodies  to  the 
islet hormones insulin (Fig. 2  C), glucagon, and somatosta- 
tin  (data not shown).  The time  course of insulitis  develop- 
ment was analyzed in more detail by evaluating the rate and 
magnitude  of the inflammatory infiltrate  in pancreata from 
NOD-IL-4  mice  and  their  nontransgenic  littermates  at 
varying ages  (Fig.  3).  In both groups,  periinsulitis  was ap- 
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Figure 2.  Histological analysis of pancreata of NOD-IL-4 mice and 
their nontransgenic littermates. Representative hematoxylin and eosin- 
stained sections of the pancreas reveal characteristic insulitis in the pan- 
creas of  a diabetic NOD female at 5 mo of  age (A), but only weak periin- 
sulitis in  a  10-too-old  NOD--IL-4  female (/3). The  islet integrity in 
NOD-IL-4 mice was confirmed by immunocytochemistry  using an anti- 
body to insulin (C-').  Bar, 50 Izm. 
parent  at  the  earliest  age  examined  (<2  mo).  However, 
whereas NOD  mice steadily progressed to insulitis and islet 
destruction,  NOD-IL-4  mice remained  at the periinsulitis 
stage during their whole lifetime. The mononuclear cell in- 100 - 
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Figure 3.  Summary of histological analysis of pancreatic sections from 
NOD-IL-4 mice and their nontransgenic NOD littermates. Mice (three 
to five per group) were killed at various ages (<2, 2-4, >4 too), and their 
pancreata were examined for periinsulitis and insulitis. Approximately 20 
islets were scored for each pancreas. 
filtrate around the islets in NOD-IL-4  mice was compara- 
ble  in  cellular  composition  to  the  infiltrates  observed  in 
nontransgenic  littermates:  CD4 +  and  CD8 +  T  cells  and 
macrophages were  the main cell types identified by immu- 
nocytochemistry  (data  not  shown).  Apart  from  the  pan- 
creas,  the  salivary gland is the  main organ for lymphocyte 
extravasation in NOD  mice.  Interestingly, all NOD-IL-4 
mice  still  developed  heavy  sialitis in  their  submandibular 
glands,  indicating that  IL-4  induced  a  local  immunosup- 
pressive  effect  in  the  pancreas  but  not  a  generalized  im- 
mune suppression. 
To  establish  whether  "functional  tolerance"  governed 
this  profound  protection  from  insulitis  and  diabetes  in 
NOD-IL-4  mice,  islet  isografting experiments  were  per- 
formed by grafting islets from young NOD  mice under the 
kidney  capsule  of 10-11-mo-old  NOD-IL-4  mice.  4  wk 
after  surgery,  histological  analysis  of  the  kidneys  where 
these  islets  were  engrafted  revealed  that,  in  NOD-IL-4 
mice,  the grafts  were  completely free  from  infiltrating in- 
flammatory cells and that they contained intact islets stain- 
Figure 4.  Islet isografting experiments with NOD-IL-4 mice and their nontransgenic littermates. (A and/3) Transgenic expression of 1L-4 induces tol- 
erance in NOD-IL-4 mice. Islet isografts from NOD mice were tolerated by NOD-IL-4 mice as demonstrated by the presence of both oL (A) and 13 cells 
(B). (C and D) Transgenic expression of IL-4 does not protect islets from destruction by primed T cells. Islet isografts from NOD-IL-4 mice were re- 
jected in diabetic NOD recipients by an inflammatory infiltrate that left c~ cells unaffected (C) but selectively destroyed 13 cells (D). Bar, 50 ~tm. 
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Figure 5.  Transgenic expression oflL-4 in the pancreas prevents diabe- 
tes transfer. Irradiated NOD-IL-4 females and their nontransgenic female 
littermates (NOD)  were injected with splenocytes from overtly diabetic 
NOD females. Blood glucose values of recipient mice were determined at 
2,  3, and 4 wk after transfer. Number of diabetic mice/total number of 
mice is given in parentheses. 
ing  strongly  for  the  islet  hormones  insulin  and  glucagon 
(Fig.  4, A  and  B).  Consequently,  IL-4 had induced  a state 
of functional tolerance to islet antigens in NOD  mice. 
The  inhibition  of both  diabetes  and  destruction  of en- 
grafted NOD  islet cells could reflect a lack of autoreactive 
T  cells in the transgenic animal.  To create an experimental 
situation in which regulation  of autoreactive cells could be 
observed, a transfer model (7) was used in which the ability 
of in situ IL-4 to block the diabetogenic  actions of spleno- 
cytes  isolated  from  diabetic  NOD  mice  was  assessed.  To 
this  end,  8-9-wk-old,  sublethaly  irradiated  NOD-IL-4 
mice and their nontransgenic  littermates were injected with 
splenocytes  from  acutely  diabetic  NOD  mice.  Of  eight 
NOD  recipients,  seven  mice  became  overtly  diabetic 
within  2-4  wk  after  transfer,  with  blood  glucose  values 
>500  mg/dl  (Fig.  5).  In contrast,  blood  glucose values of 
all seven NOD-IL-4  recipient mice remained <200 mg/dl 
within  the 4-wk observation period after the transfer.  His- 
tological  analysis  revealed  massive  inflammatory  infiltrates 
in islets ofnontransgenic  recipients, but NOD-IL-4  recipi- 
ent mice had only periinsulitis  (date not shown), indicating 
that diabetogenic splenocytes could home to the pancreatic 
islets  but  were  not  able  to  initiate  a  destructive  autoim- 
mune  attack.  In the  converse  experiment,  islets  were  iso- 
lated from NOD-IL-4  mice and their nontransgenic  litter- 
mates and grafted into  diabetic  NOD  recipients,  in which 
islet antigen-specific T  cell memory has been demonstrated 
(26).  4  wk after surgery,  the  grafts were  removed and  ex- 
amined histologically. In control experiments, diabetic NOD 
mice  rejected  islet  isografts  from  NOD  mice,  as  demon- 
strated by a mononuclear cell infiltrate and the selective loss 
of [3 cells  (data not shown).  The same result was observed 
with  islet  isografts  from  NOD-IL-4  mice;  glucagon-pro- 
ducing  o~ cells were  clearly visible, but  no insulin  produc- 
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ing  13  cells  could  be  observed  (Fig.  4,  C  and  D).  Thus, 
whereas autoreactive  T  cells were inhibited  in the  spleno- 
cyte  transfer  model,  they  were  unaffected  in  our  grafting 
experiments. 
GAD has been implicated as being the key target antigen 
in  humans  (27)  and  by  extrapolation  in  the  NOD  mice 
based on the finding  that a  T  cell response to  GAD  coin- 
cides with the onset of insulitis  (28, 29).  It has furthermore 
been demonstrated  that this  GAD-specific response is me- 
diated by the Thl  subset. To determine whether pancreatic 
production  of IL-4 had  an influence  on  the  cytokine  pat- 
tern of GAD-reactive T  cells in NOD-IL-4  mice, spleno- 
cytes  were  isolated  from  7-8-wk-old  mice  stimulated  in 
vitro with GAD65 as described previously (29), and the su- 
pernatants were tested for the presence of IFN-~/and IL-4. 
Although  T  cells  from  NOD-IL-4  mice  released  lower 
amounts of IFN-y into the medium compared with T  cells 
from their nontransgenic littermates (0.7  •  0.24 vs. 1.03  + 
0.32  ng/ml),  the  difference did not reach statistical signifi- 
cance.  Furthermore,  supernatants  from neither  NOD  nor 
NOD-IL-4  mice  showed  any  detectable  levels  of IL-4. 
These results suggest that a switch from the  production  of 
Thl  to  Th2  cytokines  in  the  GAD-reactive  T  cell  com- 
partment present in the spleen is not the major mechanism 
by  which  NOD-IL-4  mice  are  protected  from  diabetes. 
Because of the low numbers  of infiltrating cells within  the 
pancreas itself, it has so far been very difficult to determine 
whether such a switch might be occurring at a local level. 
The data presented in this study demonstrate that in situ 
islet expression  of IL-4 is sufficient  to protect  NOD  mice 
from insulitis  and  diabetes by rendering  them functionally 
tolerant  to islet antigens,  and significantly extend previous 
findings  based  on  the  in  vivo  administration  of rlL-4  to 
prediabetic NOD  mice (30). The mechanism by which this 
profound effect is mediated is still under investigation.  Al- 
though  islets  from  NOD-IL-4  mice  produce  IL-4  in 
amounts that are sufficient to induce Th2 cells in vitro (16), 
no  immune  deviation  toward  a  Th2  cytokine-producing 
phenotype  could  be  observed  among  the  GAD-reactive 
splenocytes in NOD-IL-4  mice. However, one has to con- 
sider the possibility that a phenotype switch among autore- 
active T  cells within the pancreas might not be reflected in 
the  spleen  cell  compartment  or  that  these  cells  are  very 
short-lived (31). 
One of the puzzling features of diabetes development in 
NOD  mice is the  crucial step from periinsulitis  to insulitis 
and  concomitant  [3  cell  destruction.  Although  all  NOD 
mice start to exhibit insulitis around 3-5 wk of age, diabe- 
tes  will  ultimately  develop  in  only  in  a  portion  of these 
mice. How this immune response cascade is started in some 
animals but not in others is still unclear.  Strikingly,  NOD- 
IL-4 mice, females and males, remained at the initial peri- 
insulitis  stage for all their lives and never progressed to in- 
sulitis  and  diabetes.  Several lines  of evidence  suggest  that 
CD8 + T  cells play an essential role in the initiation  of the 
autoimmune  response to [3 cells, possibly by recruiting the 
final effector cells (32-35).  The absence ofCD8 + T  cells in 
[32-microglobulin-deficient  NOD  mice, for instance,  leads to a phenotype that is in many ways very similar to NOD- 
IL-4 mice,  as  both  strains  develop  only mild  periinsulitis 
but  no  insulitis  or diabetes.  Downregulation  or deregula- 
tion of the  CD8 + T  cell compartment by IL-4 in NOD- 
IL-4 mice could therefore be a likely explanation  for our 
findings.  Indeed, Sad and Mosmann (36)  recently reported 
that differentiated CD8 + TC1  cells,  when exposed to IL-4 
in vitro, lost their ability to synthesize IL-2 and were thus 
unable  to  proliferate,  suggesting  that  IL-4 in  vivo  might 
downregulate a TC1 response by preventing the clonal ex- 
pansion of these  effector ceils.  It is conceivable that in the 
case  of NOD-IL-4  mice,  this  mechanism would result in 
the  abrogation  of the  immune  response  cascade  and  thus 
stop  the  disease  development  at  the  periinsulitis  stage. 
Committed TC1  ceils present in splenocytes from diabetic 
NOD  mice  could  be  regulated  by  IL-4 in  similar  ways, 
thus  inhibiting  the  transfer  of  disease  into  NOD-IL-4 
mice. In addition to affecting TCl  cells,  IL-4 might also act 
on macrophages  in  the  pancreas  by inhibiting  their  nitric 
oxide  (37,  38)  and TNF-ot production  (39).  Interestingly, 
islets  from  NOD-IL-4  mice  grafted  into  diabetic  NOD 
mice were not protected from destruction,  a seeming con- 
tradiction  to  the  splenocyte  transfer  experiments.  How- 
ever, the immune response to an ectopically placed isograft 
is likely to be aggravated by an inflammatory response due 
to the  operation procedure  itself and  can  thus  not readily 
be  compared with  the  immune  response  observed to  en- 
dogenous islets. 
This  is also the first  report  of a localized peripheral  ap- 
proach  to  the  diversion  of autoreactivity,  demonstrating 
that the targeted immune intervention aiming to restore an 
immune balance is feasible. Although the etiology of diabe- 
tes in the NOD  mouse is not yet understood, the presence 
of autoreactive  cells  has implied a defective negative selec- 
tion  in  the  thymus.  However,  that  islet  immunogenicity 
could now be corrected at this peripheral site suggests that a 
systemic defect is not the primary cause of diabetes.  On the 
contrary,  it  seems  that  before  disease  onset,  islet  antigen- 
naive T  cells  emerge from the thymus and migrate through 
blood and lymph until antigen is encountered.  The site of 
this  priming  event  is  debated,  however,  our  experiments 
clearly demonstrate  that regulation can occur from the re- 
mote islet site.  Thus immune therapy by localized expres- 
sion of IL-4 is a worthwhile  consideration in approaching 
insulin-dependent  diabetes  mellitus,  having the  advantage 
of not inducing global immunosuppression. 
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